| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we investigate the usefulness of plasma exosome microRNA panel as a new predictive biomarker for early diagnosis of recurrence, prognosis and the assessment of therapeutic effect in 530 colorectal cancer (CRC) patients. In healthy individuals, all microRNA in this panel showed negative. In early stage CTC patients, some microRNA showed positive. We examined the usefulness of this panel for prediction of prognosis. It was demonstrated that the microRMA panel was an important factor in the selection of recurrent high-risk patients and poor prognosis patients. We studied the value of this panel in monitoring of therapeutic effects of patients treated with chemotherapeutic agents and molecular targeting drugs. The results of the microRNA panel were associated with RECIST, which showed low levels in PR/CR cases and high levels in PD cases. These results demonstrate the usefulness of the microRNA panel in both prediction of prognosis and the monitoring of treatment effect.
|
